PCI术后阿司匹林与氯吡格雷单药治疗比较:STOPDAPT-3试验1年随访
STOPDAPT-3试验二次分析纳入5833例ACS或高出血风险PCI患者,随机接受1个月双联抗血小板后阿司匹林单药或1个月普拉格雷后氯吡格雷单药,30天界标分析显示两组1年内心血管复合终点和出血终点发生率相似。
要点
- PCI术后1个月后阿司匹林单药与氯吡格雷单药的心血管和出血结局无显著差异。
- 研究纳入ACS或高出血风险患者,中位年龄73岁,ACS占74.6%,高出血风险占54.1%。
- 1年时两组继续单药治疗比例分别为87.5%和87.2%。
核心结论
- 阿司匹林单药与氯吡格雷单药在PCI术后1个月至1年期间的心血管和出血结局相似。
研究设计与样本
- STOPDAPT-3试验的二次分析,30天界标分析,纳入5833例接受药物洗脱支架PCI的ACS或高出血风险患者。
临床怎么用
- 对于ACS或高出血风险PCI患者,短程双联抗血小板后选择阿司匹林或氯吡格雷单药均可考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: There was no previous trial comparing aspirin monotherapy with a P2Y12 inhibitor monotherapy following short dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents. METHODS: In the STOPDAPT-3, patients with acute coronary syndrome or high bleeding risk (HBR) were randomly assigned to either 1-month dual antiplatelet therapy with aspirin and prasugrel followed by aspirin monotherapy (aspirin group) or 1-month prasugrel monotherapy followed by clopidogrel monotherapy (clopidogrel group). This secondary analysis compared aspirin monotherapy with clopidogrel monotherapy by the 30-day landmark analysis. The co-primary endpoints were the cardiovascular endpoint defined as a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischaemic stroke and the bleeding endpoint defined as Bleeding Academic Research Consortium 3 or 5. RESULTS: Of the 6002 assigned patients, 5833 patients (aspirin group: N = 2920 and clopidogrel group: N = 2913) were included in the 30-day landmark analysis. Median age was 73 (interquartile range 64-80) years, women 23.4%, acute coronary syndrome 74.6%, and high bleeding risk 54.1%. The assigned monotherapy was continued at 1 year in 87.5% and 87.2% in the aspirin and clopidogrel groups, respectively. The incidence rates beyond 30 days and up to 1 year were similar between the aspirin and clopidogrel groups for both cardiovascular endpoint [4.5 and 4.5 per 100 person-year, hazard ratio 1.00 (95% confidence interval .77-1.30), P = .97], and bleeding endpoint [2.0 and 1.9, hazard ratio 1.02 (95% confidence interval .69-1.52), P = .92]. CONCLUSIONS: Aspirin monotherapy compared with clopidogrel monotherapy was associated with similar cardiovascular and bleeding outcomes beyond 1 month and up to 1 year after percutaneous coronary intervention with drug-eluting stents (STOPDAPT-3 ClinicalTrials.gov number, NCT04609111).
引用
- Watanabe H, Natsuaki M, Morimoto T, et al. Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial. Eur Heart J. 2024. PMID: 39215959. doi:10.1093/eurheartj/ehae617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。